Search clinical trials for: BIIB059 (litifilimab)

Total 177 results

Biogen

Withdrawn

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-2)

Trigeminal Neuralgia
Biogen

Completed

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Healthy Volunteer | Alzheimer's Disease

United States
Biogen

Terminated

Single Ascending Doses of BIIB063 in Healthy Volunteers

Healthy

United Kingdom
Biogen

Completed

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Multiple Sclerosis | Acute Optic Neuritis

United States
Biogen

Completed

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Multiple Sclerosis | Central Nervous System (CNS) Demyelinating Disease

United Kingdom
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
Biogen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants

Healthy Volunteers

New Zealand, Hong Kong
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Biogen

Terminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (EXPER-CA/IL)

Relapsing Forms of MS

Israel
Biogen

Completed

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (CN002-003)

Progressive Supranuclear Palsy

United States
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
Biogen

Completed

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

Healthy Volunteer

United States
Biogen

Terminated

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)

Cognitive Dysfunction | Alzheimer's Disease

United States
Biogen

Terminated

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

Alzheimer's Disease

United States, Spain, Belgium, Switzerland, Poland, Canada, Italy, Germany, Netherlands, Sweden, France, Japan, Finland
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Biogen

Active, not recruiting

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

Spinal Muscular Atrophy

United States, Taiwan, Israel, Australia, Qatar, United Kingdom, Turkey, Italy, Germany, Argentina, Canada
University of California, San Francisco

Terminated

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES (TauBasket)

Nonfluent Aphasia, Progressive | Primary Tauopathies | Corticobasal Degeneration Syndrome | Frontotemporal Lobar Degeneration With Tau Inclusions | MAPT Mutation Carriers, Symptomatic | Traumatic Encephalopathy Syndrome

United States
Biogen

Completed

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
Biogen

Completed

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Healthy

United Kingdom
Biogen

Completed

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Biogen

Terminated

Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy

Diabetes Mellitus | Small Fiber Neuropathy

Bulgaria, Poland, Spain, United Kingdom, Canada, France, Czechia, Germany, Hungary, Greece, Denmark, Italy, Netherlands, Switzerland
Biogen

Approved for marketing

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

United States
Biogen

Withdrawn

Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy

Diabetic Neuropathies | Healthy Volunteers
Biogen

Active, not recruiting

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

Alzheimer's Disease

Canada, United States, Spain, Italy, Australia, Belgium, Portugal, Korea, Republic of, United Kingdom, France, Germany, Sweden, Japan, Brazil, Finland, Poland, Mexico
Biogen

Completed

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Tauopathies

United States
Biogen

Completed

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

GIST

United States
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Healthy Volunteers

United States
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biogen

Completed

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Biogen

Completed

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Biogen
Ionis Pharmaceuticals, Inc.

Completed

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Amyotrophic Lateral Sclerosis

United States, Canada, Belgium, France, Australia, Japan, Denmark, Korea, Republic of, United Kingdom, Germany, Italy, Poland
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Biogen

Completed

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Healthy

Netherlands, United States
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

Long-Term Evaluation of BIIB067 (Tofersen)

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

United States, Canada, Italy, Belgium, New Zealand, Japan, France, Germany, United Kingdom
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

Bipolar Disorder | Bipolar Depression

United Kingdom
Biogen

Completed

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

Healthy Volunteer

United States
Biogen

Terminated

Study of Diroximel Fumarate in the Real-World Setting

Relapsing Forms of MS

United States
Biogen

Completed

Long-Term Assessment of Remyelinating Therapy (RENEWED)

Acute Optic Neuritis

Sweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
Biogen

Completed

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Systemic Lupos Erythematosus, SLE

United States

3

Subscribe